G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology biopharmaceutical company, will be hosting a webcast and conference call to provide a financial and corporate update for the first quarter of 2024 on Wednesday, May 1, 2024, at 8:30 a.m. ET. To register for the event and receive a dial-in number and unique PIN to access the live conference call, please follow the link provided to register online. It is recommended to join 10 minutes prior to the start of the event.
G1 Therapeutics is focused on developing next-generation therapies that improve the lives of those affected by cancer. Their first commercial product is COSELA® (trilaciclib), which is used in combination with cytotoxic therapies and/or immunotherapy in areas of high unmet need such as triple-negative breast cancer and extensive stage small cell lung cancer. The company’s goal is to provide innovative therapeutic advances for individuals living with cancer. Based in Research Triangle Park, N.C., G1 Therapeutics aims to improve patient outcomes through their advanced treatments.
For more information about G1 Therapeutics, visit
